アブストラクト
Japanese
| Title | 急性・慢性心不全診療ガイドライン 各分野のガイドラインを紐解く |
|---|---|
| Subtitle | カレントトピックス |
| Authors | 安斉俊久 |
| Authors (kana) | |
| Organization | 北海道大学大学院医学研究院 循環病態内科学教室 |
| Journal | 北海道外科雑誌 |
| Volume | 65 |
| Number | 1 |
| Page | 18-22 |
| Year/Month | 2020 / 6 |
| Article | 報告 |
| Publisher | 北海道外科学会 |
| Abstract | 「要旨」心不全とは, ポンプとしての心臓の機能が低下し, 体が要求する血液を十分に送り出せなくなることによって起こる労作時息切れや呼吸困難などの一連の症状をさす症候群である. 一度発症すると, 治療により一時的には安定化するものの, やがては急性増悪を繰り返すようになり, 一般的には良性疾患と考えられているものの予後はがんと同様に不良である. 先進国においては, 心不全患者が増加の一途をたどっており, 急性増悪による入退院をいかに防ぐかが喫緊の課題となっている. 急性心不全の多くは慢性心不全の急性増悪であることから, 2018年に改訂されたガイドラインでは, これまで二つに分かれていた急性心不全と慢性心不全のガイドラインが, 急性・慢性心不全診療ガイドラインとして統合され, 左室駆出率(LVEF)による分類に基づき, これまでのエビデンスに添った診断・治療法について詳細に記載された. |
| Practice | 臨床医学：外科系 |
| Keywords | 心不全, 左室出率, バイオマーカー, ナトリウム利尿ペプチド |
English
| Title | Guideline on Diagnosis and Treatment of Acute and Chronic Heart Failure |
|---|---|
| Subtitle | Current Topics |
| Authors | Toshihisa Anzai |
| Authors (kana) | |
| Organization | Department of Cardiovascular Medicine, Hokkaido University Graduate School of Medicine |
| Journal | The HOKKAIDO JOURNAL OF SURGERY |
| Volume | 65 |
| Number | 1 |
| Page | 18-22 |
| Year/Month | 2020 / 6 |
| Article | Report |
| Publisher | Hokkaido Surgical Society |
| Abstract | [Summary] Heart failure is a syndrome consisting of dyspnea on exertion or respiratory distress due to disturbed pump function of the heart. It is caused by an imbalance between the supply of the blood flow and the demand of the whole body. Once it becomes symptomatic, the stage of heart failure keeps worsening, although the symptoms can be improved temporarily by treatment. The mortality of heart failure is as high as that for cancer; however, heart failure is considered a benign disease in general. Recently, the incidence of heart failure is increasing dramatically in Western countries and it is a major socioeconomic problem. To reduce the number of hospital admissions due to heart failure is an urgent issue. Since most of cases of acute heart failure requiring admission are due to acute exacerbation of chronic heart failure, the previously separated Japanese guidelines for acute heart failure and chronic heart failure were combined and revised in 2018. In the newest guideline, heart failure is classified by the left ventricular ejection fraction and evidence-based treatments for each category are described precisely. |
| Practice | Clinical surgery |
| Keywords |
- 全文ダウンロード： 従量制、基本料金制の方共に770円(税込) です。
参考文献
- 1) 日本循環器学会/日本心不全学会. 急性・慢性心不全診療ガイドライン(2017年改訂版). 2018年3月 http://www.j-circ.or.jp/guideline/pdf/JCS2017_tsutsui_h.pdf.
- 2) Ponikowski P, Voors AA, Anker SD, et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology(ESC)Developed with the special contribution of the Heart Failure Association(HFA)of the ESC. Eur Heart J 2016; 37: 2129-2200.
- 3) Owan TE, Redfield MM. Epidemiology of diastolic heart failure. Prog Cardiovasc Dis 2005; 47: 320-332.
- 4) Curtis LH, Whellan DJ, Hammill BG, et al. Incidence and prevalence of heart failure in elderly persons, 1994-2003. Arch Intern Med 2008; 168: 418-424.
- 5) Nagai T, Yoshikawa T, Saito Y, et al. Clinical Characteristics, Management, and Outcomes of Japanese Patients Hospitalized for Heart Failure With Preserved Ejection Fraction-A Report From the Japanese Heart Failure Syndrome With Preserved Ejection Fraction(JASPER)Registry. Circ J 2018; 82: 1534-1545.
残りの3件を表示する
- 6) Owan TE, Hodge DO, Herges RM, Jacobsen SJ, Roger VL, Redfield MM. Trends in prevalence and outcome of heart failure with preserved ejection fraction. N Engl J Med 2006; 355: 251-259.
- 7) Pitt B, Pfeffer MA, Assmann SF, et al. Spironolactone for heart failure with preserved ejection fraction. N Engl J Med 2014; 370: 1383-1392.
- 8) Lam CSP, Voors AA, de Boer RA, et al. Heart failure with preserved ejection fraction: from mechanisms to therapies. Eur Heart J 2018; 39: 2780-2792.
